福元医药：盐酸溴己新口服溶液获药品注册证书

Core Viewpoint - Fuyuan Pharmaceutical (601089) has received a drug registration certificate from the National Medical Products Administration for its oral solution of bromhexine hydrochloride, indicating a significant milestone in its product development and market entry [1] Company Summary - Fuyuan Pharmaceutical's wholly-owned subsidiary, Fuyuan Pharmaceutical Co., Ltd., has been granted a registration certificate for bromhexine hydrochloride oral solution, with specifications of 40ml:80mg and 100ml:0.2g [1] - The drug is indicated for symptomatic treatment of respiratory diseases related to mucus secretion or clearance disorders in adults, adolescents, and children aged 6 and above [1] - The company invested a total of RMB 2.389 million in the research and development of this drug as of the announcement date [1] Industry Summary - According to data from Minet, the sales revenue of bromhexine hydrochloride oral solution in China's three major terminal markets is approximately RMB 18.57 million for 2024 [1] - The approval of this drug may enhance Fuyuan Pharmaceutical's competitive position in the respiratory treatment market [1]